Selected News from Today's FirstWord

Bristol-Myers Squibb to purchase ZymoGenetics for $885 million
by Lianne Dane

Bristol-Myers Squibb announced Tuesday that it entered into a definitive agreement to purchase ZymoGenetics in a deal valued at approximately $885 million, or approximately $735 million net of cash acquired. "The acquisition of ZymoGenetics brings us full ownership of a promising investigational biologic that strengthens our very diversified Hepatitis C portfolio," noted Bristol-Myers Squibb CEO Lamberto Andreotti. Full story

• US appeals court declines to reconsider pay-for-delay patent settlement ruling - (Ref. The Wall Street Journal; Yahoo!News)
• GlaxoSmithKline's head of R&D says bid for Genzyme would "not make sense" - (Ref. FinanzNachrichten; Les Echos; Trading Markets)
• Johnson & Johnson seeks damages from Merck & Co. over Remicade, Simponi - (Ref. FinanzNachrichten; Morningstar; Yahoo!Finance)
• Roche, reMYND enter into agreement to develop Alzheimer's, Parkinson's disease drugs - (Ref. Romandie; Yahoo!Finance; reMYND)
• Allergan investors file lawsuit against company directors over Botox marketing - (Ref. Bloomberg; NASDAQ)

Also in the News

• Products:
• bafetinib,
• dopamine,
• linezolid,
• lithium,
• Treanda,
• valproate,
• Xeomin

• Companies:
• Allergan,
• Biovail,
• Lilly,
• Momenta,
• Neurogenetic Pharmaceuticals,
• PolyTherics,
• sanofi-aventis

• Markets:
• EU,
• Germany,
• US

Most Read Stories in the Past Week

• Roche announces launch of cost-cutting programme
• Study: Osteoporosis drugs may increase risk of oesophageal cancer
• Report: Sanofi-aventis may raise its takeover bid for Genzyme
• UK regulatory agency says Avandia "no longer has a place on the market"
• Novartis moves forward with sale of ophthalmic drug to Bausch & Lomb